Endurant Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-311,944
| Closed | -$243K | – | 28 |
|
|
2023
Q3 | $243K | Sell |
311,944
-509,094
| -62% | -$397K | 0.22% | 43 |
|
|
2023
Q2 | $759K | Sell |
821,038
-839,797
| -51% | -$777K | 0.66% | 24 |
|
|
2023
Q1 | $1.81M | Sell |
1,660,835
-72,401
| -4% | -$78.9K | 0.93% | 28 |
|
|
2022
Q4 | $2.53M | Sell |
1,733,236
-55,281
| -3% | -$80.7K | 1.03% | 21 |
|
|
2022
Q3 | $1.92M | Sell |
1,788,517
-35,548
| -2% | -$38.2K | 0.63% | 32 |
|
|
2022
Q2 | $3.1M | Sell |
1,824,065
-336,825
| -16% | -$573K | 1.09% | 21 |
|
|
2022
Q1 | $4.45M | Buy |
2,160,890
+1,263,311
| +141% | +$2.6M | 1.17% | 22 |
|
|
2021
Q4 | $3.37M | Sell |
897,579
-19,909
| -2% | -$74.7K | 0.81% | 29 |
|
|
2021
Q3 | $4.74M | Sell |
917,488
-621,947
| -40% | -$3.22M | 1.08% | 23 |
|
|
2021
Q2 | $6.56M | Buy |
1,539,435
+623,724
| +68% | +$2.66M | 1.8% | 22 |
|
|
2021
Q1 | $4.86M | Sell |
915,711
-162,466
| -15% | -$863K | 1.27% | 30 |
|
|
2020
Q4 | $5.81M | Buy |
1,078,177
+503,675
| +88% | +$2.71M | 2.1% | 18 |
|
|
2020
Q3 | $4.59M | Buy |
574,502
+91,399
| +19% | +$729K | 1.36% | 23 |
|
|
2020
Q2 | $4.84M | Buy |
483,103
+323,277
| +202% | +$3.24M | 0.27% | 21 |
|
|
2020
Q1 | $435K | Buy |
+159,826
| New | +$435K | 0.2% | 48 |
|